Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday ...

Bright Minds Biosciences (TSE:DRUG) has released an update. Bright Minds Biosciences is teaming up again with Firefly Neuroscience to analyze ...

Bright Minds Biosciences is working with Firefly Neuroscience, an AI healthcare company, to provide a full analysis of the electroencephalogram data in Bright Minds' Phase 2 clinical trial evaluating ...

Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI ...

Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe ...

The headset recorded brain activity at four different timepoints around the administration of BMB-101. Jon Olsen, CEO of Firefly, expressed optimism about the AI platform's role in advancing ...

The Options are subject to vesting periods over the course of the term of the Options. About BMB-101 BMB-101 is a novel scaffold 5-HT2C Gq-protein biased agonist developed using structure-based ...

Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe ...

The headset recorded brain activity at four different timepoints around the administration of BMB-101. Jon Olsen, CEO of Firefly, expressed optimism about the AI platform's role in advancing clinical ...